AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases

• DOI: 10.1007/s00432-017-2408-4
• Publication Date: 2017-05-27T04:15:37Z
• Authors: Xiaoliang Wu; Wenjuan Ma; Qianghua Zhou; Haijuan Yan; Zuan-Fu Lim; Mayan Huang; Chuangzhong Deng; Xingsu Yu; Huifang Su; Satoshi Komo; Haixia Yang; Xinke Zhang; Sijin Wen; Zhenfeng Zhang; Patrick C. Ma
• Keywords: Hematology; GAS6

Patients with non-small cell lung cancer (NSCLC) brain metastases (BM) have poor clinical outcomes. We sought to determine if AXL–GAS6 expression can be used as independent prognostic biomarkers for NSCLC BM. retrospectively studied the medical records of 98 patients diagnosed advanced metastatic from December 2000 June 2014. Out a total metastases, 66 were identified metastases. The expressions AXL and GAS6 assessed by standard immunohistochemistry correlated clinicopathological factors overall survival (OS) was positively associated (P < 0.001), tumor differentiation = 0.014) in displayed no association gender, age, smoking history, pathology, T stage, N CEA, LDH. In univariate analysis, both found predict worse OS outcomes (AXL: HR 1.77, 95% CI 1.13–2.79, P 0.01; GAS6: 1.80, 1.14–2.84, 0.01). metastasis subgroup, 0.001). Both BM-OS analysis 2.19, 1.33–4.10, 0.005; 2.04, 1.01–3.71, 0.019). multivariate high co-expression AXL/GAS6 an unfavorable risk factor study population (HR 2.33, 1.40–3.87, 0.0011) also BM 2.76, 1.45–5.25, predicting outcome. represents potential biomarker outcome patients.